Tinnitus

What changes during this transition

Chronic subjective tinnitus is the dominant presentation — perception of sound (ringing, buzzing, hissing, roaring) without an external source, persisting more than 3 months. Adjacent presentations carry separate workups: somatic tinnitus (modulated by head, neck, or jaw movement; cervical or temporomandibular contribution) routes through physical therapy and dental / cervical evaluation; pulsatile tinnitus (synchronized with heartbeat) is a vascular rule-out (carotid stenosis, arteriovenous malformation, intracranial hypertension, dural arteriovenous fistula) requiring MRI / MRA / MRV imaging and is NOT a peptide conversation; Ménière's-associated tinnitus routes through the Ménière's-specific intervention sequence (low-sodium diet, diuretics, intratympanic gentamicin or steroids, endolymphatic sac surgery in severe cases). Standard workup includes audiogram with bone and air conduction, tympanometry, and ENT / otology referral; MRI is indicated for asymmetric, unilateral, or pulsatile presentations to rule out acoustic neuroma / vestibular schwannoma or vascular causes. Standard-of-care is well-established and peptide-distant. The AAO-HNS 2014 clinical practice guideline names cognitive behavioral therapy for tinnitus (CBT-T) as the strongest-evidence intervention, with tinnitus retraining therapy (TRT) and sound therapy / masking as established adjuncts — all targeting the limbic and autonomic amplification of the tinnitus percept (Jastreboff neurophysiological model) rather than the cochlear damage itself. Hearing aids are first-line in the hearing-loss subset and frequently underused. Bimodal stimulation has reshaped the device-side conversation: Lenire (Neuromod) received FDA De Novo authorization March 2023 based on the TENT-A1, TENT-A2, and TENT-A3 trials showing meaningful and durable Tinnitus Functional Index improvement at 12 months in moderate-to-severe chronic subjective tinnitus; the Auricle / Susan Shore bimodal device (University of Michigan, targeting fusiform-cell auditory-somatosensory plasticity) is in clinical development with a separate paradigm. No drug is FDA-approved for tinnitus; AM-101 (Auris Medical intratympanic esketamine) and Sonsuvi / OTO-104 (Otonomy intratympanic dexamethasone) both failed Phase 3. Off-label pharmacotherapy options carry limited evidence: amitriptyline and nortriptyline for tinnitus-related sleep and mood, gabapentin in select subsets, and benzodiazepines with dependence risk and 2020 FDA-boxed-warning context. For sudden sensorineural hearing loss (SSNHL) presenting with tinnitus, the AAO-HNS 2019 SSNHL guideline names oral corticosteroid taper or intratympanic dexamethasone within the first 2-4 weeks as the load-bearing intervention — that acute window is otology-emergency territory, not a peptide conversation. The peptide library's role here is narrow and editorially specific. B12-methylcobalamin (Tier 2 surfaced) is the rule-out before users escalate to off-label antidepressants, gabapentin, benzodiazepines, or device-based interventions — Shemesh 1993 and Singh 2016 documented elevated functional B12 deficiency prevalence in chronic tinnitus cohorts, with symptomatic improvement after repletion in the confirmed-deficient subgroup. MMA + homocysteine are the load-bearing markers; serum B12 is unreliable in the gray zone. If both are normal, B12 is not the answer and the conversation belongs back with CBT-T and audiology. Cerebrolysin (Tier 3 surfaced) is the SSNHL-adjacency case — Russian, Chinese, and Eastern European otology cohorts have used Cerebrolysin as a cochlear-and-central-auditory-neurorecovery adjunct in idiopathic SSNHL during the acute window (first 4 weeks), layered on top of the AAO-HNS 2019 corticosteroid standard-of-care. Independent replication outside the source jurisdiction is absent, Cerebrolysin is NOT in the AAO-HNS 2019 SSNHL guideline, and the tier reflects the cross-jurisdictional evidence gap, not the quality of the source-jurisdiction work itself. For chronic established subjective tinnitus without a recent SSNHL event, the case collapses. What is NOT surfaced and why. Selank (substrate-only) addresses the anxiety + autonomic-hyperarousal overlay specifically — 25-50% of chronic tinnitus cohorts carry clinical anxiety, the Russian Ministry of Health 2009 GAD + neurasthenia registration is the load-bearing indication anchor, and the benzodiazepine-sparing context (Zozulya 2008 head-to-head against medazepam) is editorially relevant in a population carrying elevated chronic-benzo prescribing. But TFI loudness and intrusiveness subscales should NOT be expected to move on Selank — what may move is the emotional-distress and concentration subscales by proxy of treating the anxiety, and CBT-T is the better-evidenced answer for that overlay. Substrate exists for honest /ask answers, NOT discovery elevation. BPC-157 (substrate-only) has zero published tinnitus research in any jurisdiction — the Sikiric Zagreb corpus is gastric mucosa and tendon / ligament rodent work, the community 'inner-ear circulation' framing extrapolates far past where the research has gone, tinnitus pathophysiology is structurally different from the gastric and tendon biology BPC was characterized in, and WADA S0 status is a hard regulatory stop for tested athletes. Semax (substrate-only) addresses the cognitive-load and concentration overlay through the tinnitus-attentional-capture phenomenon, but there's no Semax tinnitus trial in any jurisdiction and the Rule 6 non-propagation distance from registered cerebrovascular-cognitive-deficit indication to tinnitus-attentional-overlay is significant. All three exist as substrate for honest /ask answers when users probe — not as discovery options to elevate.